Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 676 to 684 of 684 results for kidney or kidneys or renal

  1. Patients with rare blood disorders to receive new treatment option, says NICE

    In final guidance published today (20 May 2021), NICE has recommended ravulizumab (Ultomiris, Alexion Pharmaceuticals) as a treatment for paroxysmal nocturnal haemoglobinuria (PNH). Draft guidance published 19 May 2021 also recommends the treatment for atypical haemolytic uraemic syndrome (aHUS).

  2. New treatment option recommended for people with type 2 diabetes

    Around 180,000 people with difficult to manage type 2 diabetes could benefit from tirzepatide as new treatment option for type 2 diabetes.

  3. Adults with Von Hippel-Lindau disease to benefit from new treatment

    NICE has recommended belzutifan for some adults with Von Hippel-Lindau disease, in final draft guidance, which could benefit up to 100 people.

  4. Dementia: target organ damage (new diagnoses) (IND80)

    This indicator covers the percentage of patients with a new diagnosis of dementia recorded in the preceding 1 April to 31 March with a record of FBC, calcium, glucose, renal and liver function, thyroid function tests, serum vitamin B12 and folate levels recorded between 6 months before or after entering on to the register. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM09

  5. Hundreds of people in England to benefit from take-at-home tablet bladder cancer treatment

    Today, for the first time, we have given the green light to a targeted treatment for the most common form of bladder cancer.

  6. NICE recommends innovative treatment for severe blood disorder for NHS use

    Caplacizumab, with plasma exchange and immunosuppression, will be used to treat acute acquired thrombotic thrombocytopenic purpura.

  7. People at risk of severe COVID-19 to have access to antiviral Paxlovid

    A further 1.4 million people who have an increased risk for progression to severe COVID-19 will be eligible for Paxlovid if they test positive.

  8. NICE recommends new treatment for rare blood disorder

    Hundreds of people with a rare blood disorder have access to a new treatment regimen following draft guidance from NICE.

  9. New NICE quality standard identifies improvements in UTI diagnosis for women

    Health professionals should diagnose women under 65 with a urinary tract infection (UTI) if they have two or more key urinary symptoms.